drugset / Trial / NCT00834535
Cefdinir Capsules 300 mg, Non-fasting
RandomizedCrossoverOpen-labelOther
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 300 mg Cefdinir Capsules manufactured and distributed by TEVA pharmaceuticals USA with that of OMNICEF® Capsules by CEPH International Corporation for Abbott Laboratories following a single oral dose (1 x 300mg capsule) in healthy adult subjects administered under non-fasting conditions.
Timeline
- Start
- 2005-07
- Primary completion
- 2005-08
- Completion
- 2005-08
Outcome
Met primary endpoint
registry Ratio of the T/R geometric mean x 100 100.83 (90% CI 93.98 to 108.17) NCT00834535 ↗
registry Ratio of the T/R geometric mean x 100 96.1 (90% CI 92.14 to 100.22) NCT00834535 ↗
registry Ratio of the T/R geometric mean x 100 96.57 (90% CI 92.8 to 100.49) NCT00834535 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cefdinir | Other / unclassified | 300 mg | Oral |
Indications
No indication recorded.